SynBioBeta Speaker
Theofanis Karaletsos
Achira
Co-founder
I am a co-founder of Achira.ai, at the interface of statistical physics, AI, and biomolecular simulation for drug discovery. Most recently, I served as Head of AI for Science at the Chan Zuckerberg Initiative, where I built and led the AI for Science organization around virtual cell modeling. Previously: VP AI at Insitro, Staff Research Scientist at Meta, founding member of Uber AI Labs, and researcher at Geometric Intelligence.
Sessions Featuring
Theofanis
This Year
•
-
AIxBIO
Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models
The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?
Featuring
Gabriele Corso
Boltz
CEO
Built DiffDock and the Boltz open-source models reshaping drug discovery.
Peter Clark
Novo Nordisk
VP, CDD
Computational drug-design leader, shipped candidates from CAR-T to peptides.
Theofanis Karaletsos
Achira
Co-founder
Tanja Kortemme
UCSF
Vice Dean of Research
De novo protein-design pioneer; NIH Pioneer Award winner.
Elliot Hershberg
Amplify Partners
Partner, Author
Driving the Century of Biology
•
-
AIxBIO
Beyond Static Predictions — AI for Protein Dynamics and Multi-Cell Models
The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?
Featuring
Gabriele Corso
Boltz
CEO
Built DiffDock and the Boltz open-source models reshaping drug discovery.
Peter Clark
Novo Nordisk
VP, CDD
Computational drug-design leader, shipped candidates from CAR-T to peptides.
Theofanis Karaletsos
Achira
Co-founder
Tanja Kortemme
UCSF
Vice Dean of Research
De novo protein-design pioneer; NIH Pioneer Award winner.
Elliot Hershberg
Amplify Partners
Partner, Author
Driving the Century of Biology
